Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study
- 12 April 2020
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (10) , 2781-2792
Abstract
Background Botulinum toxin (BT) is an effective and safe treatment for spasticity, with limited evidence in multiple sclerosis (MS). We aim to describe the use of BT for the management of MS spasticity in the clinical practice, its combination with other anti-spastic treatments in MS and possible MS clinical correlates. Methods This is a multicentre cross-sectional observational study including 386 MS patients, receiving BT for spasticity in 19 Italian centres (age 53.6 ± 10.9 years; female 228 (59.1%); disease duration 18.7 ± 9.2 years; baseline Expanded Disability Status Scale (EDSS) 6.5 (2.0–9.0)). Results BT was used for improving mobility (n = 170), functioning in activities of daily living (n = 56), pain (n = 56), posturing-hygiene (n = 63) and daily assistance (n = 41). BT formulations were AbobotulinumtoxinA (n = 138), OnabotulinumtoxinA (n = 133) and IncobotulinumtoxinA (n = 115). After conversion to unified dose units, higher BT dose was associated with higher EDSS (Coeff = 0.591; p < 0.001), higher modified Ashworth scale (Coeff = 0.796; p < 0.001) and non-ambulatory patients (Coeff = 209.382; p = 0.006). Lower BT dose was used in younger patients (Coeff = − 1.746; p = 0.009), with relapsing-remitting MS (Coeff = − 60.371; p = 0.012). BT dose was higher in patients with previous BT injections (Coeff = 5.167; p = 0.001), and with concomitant treatments (Coeff = 43.576; p = 0.022). Three patients (0.7%) reported on post-injection temporary asthenia/weakness (n = 2) and hypophonia (n = 1). Conclusion BT was used for spasticity and its consequences from the early stages of MS, without significant adverse effects. MS-specific goals and injection characteristics can be used to refer MS patients to BT treatment, to decide for the strategy of BT injections and to guide the design of future clinical trials and observational studies.Keywords
This publication has 46 references indexed in Scilit:
- A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremorNeurology, 2012
- Validation of the Comprehensive ICF Core Set for Multiple Sclerosis from the perspective of occupational therapistsScandinavian Journal of Occupational Therapy, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- The place of the botulinum toxin in the management of multiple sclerosisClinical Neurology and Neurosurgery, 2010
- REPAS, a summary rating scale for resistance to passive movement: Item selection, reliability and validityDisability and Rehabilitation, 2008
- Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosisClinical Rehabilitation, 2007
- Use of international classification of functioning, disability and health (ICF) to describe patient-reported disability in multiple sclerosis and identification of relevant environmental factorsJournal of Rehabilitation Medicine, 2007
- Spasticity after spinal cord injurySpinal Cord, 2005
- Anti-spasticity agents for multiple sclerosisCochrane Database of Systematic Reviews, 2003
- Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging studyJournal of Neurology, Neurosurgery & Psychiatry, 2000